HRI awarded prestigious Ramaciotti grant

Dr Sanjay Patel, Group Leader at the Heart Research Institute, has been awarded a highly prestigious Ramaciotti Grant to pursue his work developing a cost-effective therapy to prevent heart attack and stroke.

The five Ramaciotti Health Investment Grants of $150,000 are awarded to autonomous early career scientists to support health or medical research with a potential path to clinical application within five years.

The grant will allow Dr Patel to pursue his work developing a novel cost-effective therapy to stop the progression of atherosclerosis before it leads to heart attack and stroke.

This project targets inflammation, by testing the cardio-protective properties of colchicine, a widely available and cost-effective anti-inflammatory drug that has long been used to treat arthritis caused by gout.

Dr Patel, who is also an interventional cardiologist at Royal Prince Alfred Hospital Hospital, discovered that colchicine, can significantly improve heart health by lowering the levels of dangerous inflammatory proteins.

Inflammatory cells and proteins play a critical role in atherosclerosis, fat build-up in the vessel wall, the leading cause of death and disability in Australia. Despite current best treatments, many people remain at high risk of cardiovascular complications such as stroke, or heart attack – which claims the life of someone in Australia every 24 minutes.

"If we're able to prove its success in larger studies, we'll have a brand new therapy that will considerably brighten the outlook for people who suffer heart attacks," said Dr Patel

In initial studies, Dr Patel studied 40 people with acute coronary syndrome, a life-threatening condition in which the coronary blood vessel is blocked, causing heart attack or severe chest pain.

“In these studies we are able to treat patients straight away, and have already in preliminary research,” he said.

“It is highly likely that successful studies will lead to colchicine becoming a clinical treatment for atherosclerosis within the next five years, decreasing the risk of heart attack and stroke for more than 230,000 people in Australia with atherosclerosis.”

Patients who have the condition have plaques on their arteries causing the blockages, and often have high levels of some inflammatory markers, known as Interleukins β, 18 and 6, in their blood.

"We know from pathology and histology that when you take coronary arteries from patients who have died, the plaques are just full of inflammatory markers and proteins," he said.

"Inflammation is really intimately involved with every stage of the disease."

The Ramaciotti Foundation is one of the biggest and most prestigious philanthropic contributors to medical research in Australia, awarding just five Health Investment Grants each year. Previous Ramaciotti winners having been responsible for the development of the world’s first cervical cancer vaccines and the Cochlear implant, highlighting the significant impact that philanthropy can have on the wellbeing of millions of people.

Husband and wife team Professor Jane Visvader and Professor Geoff Lindeman, of the Walter and Eliza Hall Institute of Medical Research, were selected as the joint recipients of the Ramaciotti Medal for Excellence in Biomedical Research, an annual award of $50,000 to honour an outstanding discovery in clinical or experimental biomedical research.  Professors Visvader and Lindeman received the medal for their pioneering work in discovering new approaches to breast cancer treatment and prevention.

Perpetual is a trustee of the Clive and Vera Ramaciotti Foundation.

Congratulations to all the Ramaciotti Health Investment Grants recipients!


Project Title

Dr Jane Kohlhoff


The ‘Watch Me Grow’ App for identification of developmental and mental health problems in early childhood: a validation study

A/Professor Lyndell Lim Centre for Eye Research Australia Improving cataract surgery outcomes in patients with Diabetic Macular Oedema (the DiMeCAT Trial)
A/Professor Philippa Middleton

South Australian Health and Medical Research Institute Ltd

Optimega: Preventing preterm birth and improving long term and intergenerational health through personalising dietary fat intake for pregnant women

Dr Sanjay Patel The Heart Research Institute

Colchicine – A novel role in stabilising vulnerable atherosclerotic plaque

Dr Mark Polizzotto

UNSW Australia (Kirby Institute for Infection and Immunity)

Immune modulation for prevention of anogenital cancer in people with persistent high-grade anal intraepithelial neoplasia



Related news

Celebrating 30 Years of Discovery

In March 2019, HRI celebrated 30 years since it opened its doors.

Read more

HRI researchers discover how biomechanical thrombus growth is mediated

Following injuries like a nick or cut, platelets that utilise the binding and signaling functions of an integrin called glycoprotein IIb/IIIa, or αIIbβ3, swarm the wound and clump together, forming a ‘plug’ or clot to stop blood loss. This first stage of wound healing is called hemostasis. However, this clumping of platelets can also cause deadly blood clots – thrombosis – which can lead to cardiovascular disorders such as heart attack or stroke.

Read more

HRI scientists pursue implant ‘Holy Grail’

In a world-first discovery, scientists at the Heart Research Institute have developed a high-tech coating that regulates the body’s often severe immune response to synthetic implants. This brings us one step closer to an exciting future where the human body does not reject lifesaving coronary bypass implants. 

Read more